Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges
In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential to promote ca...
Uloženo v:
| Vydáno v: | European heart journal Ročník 32; číslo 10; s. 1197 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.05.2011
|
| Témata: | |
| ISSN: | 1522-9645, 1522-9645 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential to promote cardiac neovascularization and to attenuate ischaemic injury, a decade of intense research has examined several novel approaches to promote cardiac repair in adult life. A variety of adult stem and progenitor cells from different sources have been examined for their potential to promote cardiac repair and regeneration. Although early, small-scale clinical studies underscored the potential effects of cell-based therapy largely by using bone marrow (BM)-derived cells, subsequent randomized-controlled trials have revealed mixed results that might relate, at least in part, to differences in study design and techniques, e.g. differences in patient population, cell sources and preparation, and endpoint selection. Recent meta-analyses have supported the notion that administration of BM-derived cells may improve cardiac function on top of standard therapy. At this stage, further optimization of cell-based therapy is urgently needed, and finally, large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality. Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischaemic heart disease. To advance the field forward, several important aspects need to be addressed in carefully designed studies: comparative studies may allow to discriminate superior cell populations, timing, dosing, priming of cells, and delivery mode for different applications. In order to predict benefit, influencing factors need to be identified with the aim to focus resources and efforts. Local retention and fate of cells in the therapeutic target zone must be improved. Further understanding of regenerative mechanisms will enable optimization at all levels. In this context, cell priming, bionanotechnology, and tissue engineering are emerging tools and may merge into a combined biological approach of ischaemic tissue repair. |
|---|---|
| AbstractList | In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential to promote cardiac neovascularization and to attenuate ischaemic injury, a decade of intense research has examined several novel approaches to promote cardiac repair in adult life. A variety of adult stem and progenitor cells from different sources have been examined for their potential to promote cardiac repair and regeneration. Although early, small-scale clinical studies underscored the potential effects of cell-based therapy largely by using bone marrow (BM)-derived cells, subsequent randomized-controlled trials have revealed mixed results that might relate, at least in part, to differences in study design and techniques, e.g. differences in patient population, cell sources and preparation, and endpoint selection. Recent meta-analyses have supported the notion that administration of BM-derived cells may improve cardiac function on top of standard therapy. At this stage, further optimization of cell-based therapy is urgently needed, and finally, large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality. Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischaemic heart disease. To advance the field forward, several important aspects need to be addressed in carefully designed studies: comparative studies may allow to discriminate superior cell populations, timing, dosing, priming of cells, and delivery mode for different applications. In order to predict benefit, influencing factors need to be identified with the aim to focus resources and efforts. Local retention and fate of cells in the therapeutic target zone must be improved. Further understanding of regenerative mechanisms will enable optimization at all levels. In this context, cell priming, bionanotechnology, and tissue engineering are emerging tools and may merge into a combined biological approach of ischaemic tissue repair.In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential to promote cardiac neovascularization and to attenuate ischaemic injury, a decade of intense research has examined several novel approaches to promote cardiac repair in adult life. A variety of adult stem and progenitor cells from different sources have been examined for their potential to promote cardiac repair and regeneration. Although early, small-scale clinical studies underscored the potential effects of cell-based therapy largely by using bone marrow (BM)-derived cells, subsequent randomized-controlled trials have revealed mixed results that might relate, at least in part, to differences in study design and techniques, e.g. differences in patient population, cell sources and preparation, and endpoint selection. Recent meta-analyses have supported the notion that administration of BM-derived cells may improve cardiac function on top of standard therapy. At this stage, further optimization of cell-based therapy is urgently needed, and finally, large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality. Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischaemic heart disease. To advance the field forward, several important aspects need to be addressed in carefully designed studies: comparative studies may allow to discriminate superior cell populations, timing, dosing, priming of cells, and delivery mode for different applications. In order to predict benefit, influencing factors need to be identified with the aim to focus resources and efforts. Local retention and fate of cells in the therapeutic target zone must be improved. Further understanding of regenerative mechanisms will enable optimization at all levels. In this context, cell priming, bionanotechnology, and tissue engineering are emerging tools and may merge into a combined biological approach of ischaemic tissue repair. In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential to promote cardiac neovascularization and to attenuate ischaemic injury, a decade of intense research has examined several novel approaches to promote cardiac repair in adult life. A variety of adult stem and progenitor cells from different sources have been examined for their potential to promote cardiac repair and regeneration. Although early, small-scale clinical studies underscored the potential effects of cell-based therapy largely by using bone marrow (BM)-derived cells, subsequent randomized-controlled trials have revealed mixed results that might relate, at least in part, to differences in study design and techniques, e.g. differences in patient population, cell sources and preparation, and endpoint selection. Recent meta-analyses have supported the notion that administration of BM-derived cells may improve cardiac function on top of standard therapy. At this stage, further optimization of cell-based therapy is urgently needed, and finally, large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality. Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischaemic heart disease. To advance the field forward, several important aspects need to be addressed in carefully designed studies: comparative studies may allow to discriminate superior cell populations, timing, dosing, priming of cells, and delivery mode for different applications. In order to predict benefit, influencing factors need to be identified with the aim to focus resources and efforts. Local retention and fate of cells in the therapeutic target zone must be improved. Further understanding of regenerative mechanisms will enable optimization at all levels. In this context, cell priming, bionanotechnology, and tissue engineering are emerging tools and may merge into a combined biological approach of ischaemic tissue repair. |
| Author | Tongers, Jörn Landmesser, Ulf Losordo, Douglas W |
| Author_xml | – sequence: 1 givenname: Jörn surname: Tongers fullname: Tongers, Jörn email: tongers.joern@mh-hannover.de organization: Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg Strasse 1, Hannover, Germany. tongers.joern@mh-hannover.de – sequence: 2 givenname: Douglas W surname: Losordo fullname: Losordo, Douglas W – sequence: 3 givenname: Ulf surname: Landmesser fullname: Landmesser, Ulf |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21362705$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1PwzAQxS1URGlhZ0LeWBpqO7bjsKGKL6kSAzBHjnNpXCVOsZ2h_z1pKRLTveH33r27GZq43gFCN5TcU5KnSxh8A9rH7RIaT6g6Q5dUMJbkkovJPz1FsxC2hBAlqbxAU0ZTyTIiLpH9iNBh7Sq88_0GnI29xwbaNil1gArHBrze7bF12AbTaOiswceduLIBRubh4OxGvcCDM-Cjti5aCItj6mhpW3AbCFfovNZtgOvTnKOv56fP1Wuyfn95Wz2uE8NzGhPOITfKUEmAZqXJCReKEmo4IXlOUl1XUpWC1rkCUrOSVVpwJaXhGa2kLDmbo7vf3LHW9wAhFmO5w0XaQT-EQsksZYwKMZK3J3IoO6iKnbed9vvi7zvsB0s7azM |
| CitedBy_id | crossref_primary_10_7603_s40730_016_0037_1 crossref_primary_10_1111_jsm_12620 crossref_primary_10_1155_2012_428403 crossref_primary_10_1093_ndt_gfs432 crossref_primary_10_1007_s00018_019_03019_2 crossref_primary_10_1038_s41551_017_0182_x crossref_primary_10_1111_jcmm_15598 crossref_primary_10_1146_annurev_immunol_032712_095919 crossref_primary_10_1002_jbio_201800219 crossref_primary_10_1016_j_bbadis_2014_05_004 crossref_primary_10_1161_CIRCRESAHA_117_312486 crossref_primary_10_1155_2016_9176357 crossref_primary_10_1002_jcb_25115 crossref_primary_10_1177_1074248414552902 crossref_primary_10_1371_journal_pone_0073304 crossref_primary_10_3109_1061186X_2012_719898 crossref_primary_10_1007_s12015_021_10168_0 crossref_primary_10_1038_cr_2015_99 crossref_primary_10_1093_eurheartj_ehv590 crossref_primary_10_1016_j_athoracsur_2019_07_093 crossref_primary_10_1007_s40139_015_0071_5 crossref_primary_10_1016_j_yjmcc_2021_08_010 crossref_primary_10_1161_HYPERTENSIONAHA_114_02440 crossref_primary_10_1016_j_freeradbiomed_2012_10_532 crossref_primary_10_1016_j_biotechadv_2017_05_006 crossref_primary_10_1016_j_jtcvs_2012_07_036 crossref_primary_10_2217_rme_12_21 crossref_primary_10_1016_j_jcyt_2015_05_003 crossref_primary_10_1016_j_pharmthera_2014_02_013 crossref_primary_10_1002_ange_201307034 crossref_primary_10_1371_journal_pone_0165926 crossref_primary_10_1161_CIRCRESAHA_113_300929 crossref_primary_10_1093_cvr_cvs109 crossref_primary_10_1093_eurheartj_ehv747 crossref_primary_10_1038_s41536_017_0032_1 crossref_primary_10_1007_s12015_012_9353_z crossref_primary_10_1161_CIRCEP_113_001050 crossref_primary_10_1089_scd_2014_0111 crossref_primary_10_3760_cma_j_issn_0366_6999_20121532 crossref_primary_10_1016_j_athoracsur_2019_05_094 crossref_primary_10_1186_s10020_020_00241_8 crossref_primary_10_1002_anie_201307034 crossref_primary_10_1038_s41401_022_00896_5 crossref_primary_10_1007_s10495_013_0881_z crossref_primary_10_1016_j_thromres_2015_11_025 crossref_primary_10_1007_s00059_016_4500_y crossref_primary_10_1016_j_lfs_2019_04_040 crossref_primary_10_1016_j_carbon_2017_05_050 crossref_primary_10_1097_CRD_0000000000000291 crossref_primary_10_1016_j_mvr_2018_05_007 crossref_primary_10_1016_j_ultrasmedbio_2015_09_010 crossref_primary_10_1093_eurheartj_ehu445 crossref_primary_10_1016_j_tice_2020_101453 crossref_primary_10_1093_eurheartj_ehr299 crossref_primary_10_1371_journal_pone_0173657 crossref_primary_10_1186_s13578_023_00960_5 crossref_primary_10_1155_2012_346735 crossref_primary_10_1155_2015_135023 crossref_primary_10_1016_j_thromres_2013_12_038 crossref_primary_10_1155_2019_7486279 crossref_primary_10_1586_erc_11_148 crossref_primary_10_1038_s41598_017_10122_6 crossref_primary_10_1038_nrcardio_2011_129 crossref_primary_10_1007_s00595_013_0528_2 crossref_primary_10_1186_s13287_021_02443_1 crossref_primary_10_1186_scrt122 crossref_primary_10_1155_2019_8723076 crossref_primary_10_1186_s13287_020_01669_9 crossref_primary_10_3390_ijms241210308 crossref_primary_10_1016_j_stem_2012_05_010 crossref_primary_10_1007_s40256_025_00741_0 crossref_primary_10_1371_journal_pone_0059020 crossref_primary_10_3389_fcvm_2023_1186574 crossref_primary_10_1007_s10557_014_6568_z crossref_primary_10_1016_j_actbio_2022_05_003 crossref_primary_10_1093_eurheartj_ehs098 crossref_primary_10_1038_aps_2013_147 crossref_primary_10_1016_j_yjmcc_2022_06_013 crossref_primary_10_1371_journal_pone_0054135 crossref_primary_10_1155_2013_918640 crossref_primary_10_1155_2015_638153 crossref_primary_10_1161_CIRCRESAHA_113_300219 crossref_primary_10_2337_db14_0004 crossref_primary_10_1016_j_biomaterials_2018_06_038 crossref_primary_10_1007_s11010_014_2165_5 crossref_primary_10_1586_erc_12_95 crossref_primary_10_1016_j_ultrasmedbio_2021_04_024 crossref_primary_10_1016_j_ejccm_2013_02_001 crossref_primary_10_1111_apha_13396 crossref_primary_10_1002_clc_22381 crossref_primary_10_1038_s41573_020_0064_x crossref_primary_10_1186_s13287_016_0390_4 crossref_primary_10_1016_j_ijcard_2015_02_084 crossref_primary_10_5966_sctm_2013_0163 crossref_primary_10_1186_s13287_019_1183_3 crossref_primary_10_1002_term_3243 crossref_primary_10_1155_2017_5237063 crossref_primary_10_1371_journal_pone_0079100 crossref_primary_10_3389_fsurg_2015_00031 crossref_primary_10_3892_ijmm_2016_2542 crossref_primary_10_1186_s13287_022_02736_z crossref_primary_10_1007_s13239_014_0193_7 crossref_primary_10_2217_fca_11_46 crossref_primary_10_1089_ars_2012_4849 crossref_primary_10_1007_s11010_015_2361_y crossref_primary_10_1007_s12265_016_9707_z crossref_primary_10_1371_journal_pone_0082997 crossref_primary_10_3727_096368914X679363 crossref_primary_10_1111_j_1582_4934_2012_01539_x crossref_primary_10_5966_sctm_2015_0177 crossref_primary_10_1517_14712598_2012_721764 crossref_primary_10_3892_etm_2019_7283 crossref_primary_10_1155_2017_9404057 crossref_primary_10_1002_stem_1414 crossref_primary_10_1016_j_avsg_2019_10_048 crossref_primary_10_1186_s13221_015_0031_1 crossref_primary_10_1007_s10741_014_9469_0 crossref_primary_10_1161_CIRCRESAHA_114_300639 crossref_primary_10_5966_sctm_2015_0281 crossref_primary_10_1155_2018_1909346 crossref_primary_10_1177_00220345221112332 crossref_primary_10_1016_j_revmed_2011_09_005 crossref_primary_10_1155_2021_6665358 crossref_primary_10_1016_j_yjmcc_2014_05_017 crossref_primary_10_1161_CIRCULATIONAHA_112_093906 crossref_primary_10_1016_j_cpcardiol_2024_102863 crossref_primary_10_3727_096368912X653282 crossref_primary_10_1002_adhm_201300063 crossref_primary_10_1016_j_biomaterials_2012_04_006 crossref_primary_10_1186_s13287_019_1238_5 crossref_primary_10_3389_fsurg_2015_00010 crossref_primary_10_1002_term_2933 crossref_primary_10_1016_j_diff_2019_12_001 crossref_primary_10_1093_eurheartj_ehv293 crossref_primary_10_1093_eurjhf_hfs137 crossref_primary_10_1161_CIRCRESAHA_115_307184 crossref_primary_10_1089_scd_2013_0194 crossref_primary_10_1097_FJC_0b013e31829372fc crossref_primary_10_3389_fcvm_2021_767488 crossref_primary_10_1161_CIRCULATIONAHA_111_047746 crossref_primary_10_1093_eurheartj_ehv049 crossref_primary_10_1016_j_biomaterials_2014_12_013 crossref_primary_10_1016_j_ijcard_2013_12_202 crossref_primary_10_1093_cvr_cvs202 crossref_primary_10_1139_y2012_031 crossref_primary_10_1007_s11897_013_0134_z crossref_primary_10_1371_journal_pone_0034344 crossref_primary_10_1016_j_jvs_2015_02_061 crossref_primary_10_1089_scd_2012_0268 crossref_primary_10_1093_eurheartj_ehv040 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/eurheartj/ehr018 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-9645 |
| ExternalDocumentID | 21362705 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL053354 – fundername: NHLBI NIH HHS grantid: R01 HL95874 – fundername: NHLBI NIH HHS grantid: R01 HL77428 – fundername: NHLBI NIH HHS grantid: R01 HL80137 – fundername: NHLBI NIH HHS grantid: R01 HL53354 – fundername: NHLBI NIH HHS grantid: R01 HL095874 |
| GroupedDBID | --- --K -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1B1 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6.Y 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABSAR ABSMQ ABVGC ABWST ABXVV ABZBJ ACFRR ACGFO ACGFS ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFIYH AFOFC AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVWKF AXUDD AZFZN BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD D~K E3Z EBS ECM EE~ EIF EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IHE IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 M49 MBLQV MHKGH ML0 N4W N9A NGC NOMLY NOYVH NPM NQ- NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RPZ RUSNO RW1 RXO RZF SEL TCURE TEORI TJX TMA UHS VH1 W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ~91 7X8 AAFWJ ABPQP ADGHP ADNBA AEMQT AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c491t-44e9c8c160e17bc90458101c4009903afd68b51f98e0f2b2da54866c471d66b42 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 204 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000290812000010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-9645 |
| IngestDate | Sat Sep 27 22:36:44 EDT 2025 Wed Feb 19 01:51:28 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c491t-44e9c8c160e17bc90458101c4009903afd68b51f98e0f2b2da54866c471d66b42 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://academic.oup.com/eurheartj/article-pdf/32/10/1197/17049274/ehr018.pdf |
| PMID | 21362705 |
| PQID | 867322155 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_867322155 pubmed_primary_21362705 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-05-01 |
| PublicationDateYYYYMMDD | 2011-05-01 |
| PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European heart journal |
| PublicationTitleAlternate | Eur Heart J |
| PublicationYear | 2011 |
| References | 19520249 - J Am Coll Cardiol. 2009 Jun 16;53(24):2262-9 16172284 - Circulation. 2005 Sep 20;112(12):1748-55 17414713 - Transplantation. 2007 Mar 27;83(6):783-90 16990384 - N Engl J Med. 2006 Sep 21;355(12):1210-21 19508995 - Eur Heart J. 2009 Aug;30(16):1986-94 15364865 - Circulation. 2004 Sep 14;110(11 Suppl 1):II213-8 17691968 - Curr Neurovasc Res. 2007 Aug;4(3):153-60 20925550 - N Engl J Med. 2010 Oct 7;363(15):1471-2 16159812 - Circulation. 2005 Aug 30;112(9 Suppl):I178-83 15001531 - Circ Res. 2004 Apr 2;94(6):e56-60 15336842 - Int J Cardiol. 2004 Jun;95 Suppl 1:S29-33 16698918 - Proc Natl Acad Sci U S A. 2006 May 23;103(21):8155-60 12714439 - Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 17562958 - Circulation. 2007 Jun 26;115(25):3165-72 17090821 - J Invasive Cardiol. 2006 Nov;18(11):552-6 20660394 - N Engl J Med. 2010 Oct 7;363(15):1397-409 19544463 - Stem Cells. 2009 Jul;27(7):1571-81 17145991 - Circulation. 2006 Dec 19;114(25):2823-30 15767470 - Hypertension. 2005 Apr;45(4):526-9 16510465 - Eur Heart J. 2006 Apr;27(8):929-35 16256862 - J Am Coll Cardiol. 2005 Nov 1;46(9):1643-8 18293890 - Cell Transplant. 2007;16(9):919-25 20861135 - Eur J Heart Fail. 2010 Oct;12(10):1111-21 19429633 - Eur Heart J. 2009 Jun;30(11):1310-2 19540842 - J Mol Cell Cardiol. 2009 Sep;47(3):411-8 18308163 - J Am Coll Cardiol. 2008 Mar 4;51(9):933-43 9701245 - Nat Med. 1998 Aug;4(8):929-33 17709737 - Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14068-73 18625890 - Circulation. 2008 Jul 29;118(5):507-17 15246726 - Lancet. 2004 Jul 10-16;364(9429):141-8 19349334 - Circulation. 2009 Apr 7;119(13):1814-23 12695305 - Circulation. 2003 Apr 29;107(16):2134-9 19342590 - Science. 2009 Apr 3;324(5923):98-102 11744011 - Cardiovasc Res. 2002 Jan;53(1):31-47 12517468 - Lancet. 2003 Jan 4;361(9351):47-9 16002755 - Circ Res. 2005 Jul 8;97(1):8-15 20421520 - Circulation. 2010 May 11;121(18):1992-2000 12473544 - Circulation. 2002 Dec 10;106(24):3009-17 15192775 - Thorac Cardiovasc Surg. 2004 Jun;52(3):152-8 18523058 - Eur Heart J. 2008 Aug;29(15):1807-18 19226183 - PLoS Med. 2009 Feb 17;6(2):e1000029 11413075 - Circulation. 2001 Jun 19;103(24):2885-90 17984132 - Eur Heart J. 2007 Dec;28(24):2998-3005 15851598 - Circulation. 2005 May 3;111(17):2198-202 17056665 - Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1095-104 18672162 - J Am Coll Cardiol. 2008 Aug 5;52(6):428-34 19738142 - Circulation. 2009 Sep 22;120(12):1075-83, 7 p following 1083 16256864 - J Am Coll Cardiol. 2005 Nov 1;46(9):1651-8 15389244 - Am Heart J. 2004 Sep;148(3):531-7 18794392 - Circulation. 2008 Sep 30;118(14):1425-32 18371446 - Cell Stem Cell. 2008 Mar 6;2(3):205-13 17592079 - Circulation. 2007 Jul 10;116(2):163-73 19099374 - Stem Cells Dev. 2009 Jun;18(5):683-92 10791985 - J Cell Biol. 2000 May 1;149(3):731-40 20083719 - Circulation. 2010 Jan 19;121(2):325-35 17283208 - J Exp Med. 2007 Feb 19;204(2):405-20 15358665 - Circ Res. 2004 Oct 1;95(7):742-8 20534467 - Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11008-13 16476845 - Circulation. 2006 Feb 21;113(7):1005-14 18556575 - Circ Res. 2008 Jul 18;103(2):194-202 18467662 - Stem Cells. 2008 Jul;26(7):1749-57 19208649 - Eur Heart J. 2009 Jun;30(11):1313-21 15321944 - Circ Res. 2004 Aug 20;95(4):343-53 11548889 - Jpn Circ J. 2001 Sep;65(9):845-7 12707230 - Circulation. 2003 May 13;107(18):2294-302 19620500 - Circulation. 2009 Aug 4;120(5):408-16 19833262 - J Am Coll Cardiol. 2009 Oct 20;54(17):1619-26 18793110 - Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1071-82 15219514 - Am J Cardiol. 2004 Jul 1;94(1):92-5 15883216 - Circulation. 2005 May 17;111(19):2486-93 19436808 - Tex Heart Inst J. 2009;36(2):140-4 20453167 - Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1088-93 16990385 - N Engl J Med. 2006 Sep 21;355(12):1222-32 19704095 - Circulation. 2009 Sep 8;120(10):876-87 20576835 - Eur J Heart Fail. 2010 Jul;12(7):721-9 16520413 - Circulation. 2006 Mar 14;113(10):1287-94 14505575 - Cell. 2003 Sep 19;114(6):763-76 15016484 - Lancet. 2004 Mar 6;363(9411):751-6 18402895 - J Am Coll Cardiol. 2008 Apr 15;51(15):1429-37 20211295 - Am Heart J. 2010 Mar;159(3):354-60 19996415 - Circ Heart Fail. 2010 Jan;3(1):89-96 17098754 - Eur Heart J. 2006 Dec;27(23):2775-83 16061805 - Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11474-9 17964040 - J Am Coll Cardiol. 2007 Oct 30;50(18):1761-7 19958962 - J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86 16582915 - Nat Med. 2006 Apr;12(4):452-8 11489932 - J Clin Invest. 2001 Aug;108(3):391-7 11851363 - J Mol Cell Cardiol. 2002 Feb;34(2):241-9 14613737 - Eur Heart J. 2003 Nov;24(22):2012-20 12628955 - Circulation. 2003 Mar 11;107(9):1322-8 19095934 - Science. 2008 Dec 19;322(5909):1811-5 12517467 - Lancet. 2003 Jan 4;361(9351):45-6 16904174 - Cell. 2006 Aug 25;126(4):663-76 17823373 - Circ Res. 2007 Oct 26;101(9):910-8 15764613 - Eur Heart J. 2005 Jun;26(12):1188-95 18288183 - Nature. 2008 Feb 21;451(7181):937-42 12679204 - J Am Coll Cardiol. 2003 Apr 2;41(7):1078-83 15242981 - Circ Res. 2004 Jul 9;95(1):9-20 18669889 - Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1584-95 16678200 - J Mol Cell Cardiol. 2006 Jun;40(6):799-809 12196341 - Circulation. 2002 Aug 27;106(9):1133-9 12370212 - Circulation. 2002 Oct 8;106(15):1913-8 19454638 - JAMA. 2009 May 20;301(19):1997-2004 19341621 - Cell Stem Cell. 2009 Apr 3;4(4):313-23 9616709 - Ann N Y Acad Sci. 1997 Dec 31;831:145-67 17875967 - Circulation. 2007 Oct 9;116(15):1683-92 16990383 - N Engl J Med. 2006 Sep 21;355(12):1199-209 9020076 - Science. 1997 Feb 14;275(5302):964-7 9462531 - Circulation. 1998 Jan 27;97(3):282-9 18566313 - Circ Res. 2008 Jun 20;102(12):1471-82 17075009 - Circulation. 2006 Nov 14;114(20):2163-9 16543252 - Eur Heart J. 2006 Jun;27(11):1338-40 18285565 - Circulation. 2008 Mar 4;117(9):1189-200 19213953 - Circ Res. 2009 Feb 27;104(4):e30-41 17283259 - Circulation. 2007 Feb 20;115(7):896-908 16159869 - Circulation. 2005 Aug 30;112(9 Suppl):I73-80 12900340 - Circulation. 2003 Aug 19;108(7):863-8 15687132 - Circulation. 2005 Feb 1;111(4):442-50 16413875 - Lancet. 2006 Jan 14;367(9505):113-21 18728188 - Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12991-6 19789401 - Eur J Heart Fail. 2009 Oct;11(10):973-9 17533201 - Arch Intern Med. 2007 May 28;167(10):989-97 15655116 - Hypertension. 2005 Mar;45(3):321-5 14680727 - J Am Coll Cardiol. 2003 Dec 17;42(12):2063-9 16003373 - Nat Biotechnol. 2005 Jul;23(7):845-56 19773226 - Eur Heart J. 2009 Dec;30(24):2978-84 15489105 - J Am Coll Cardiol. 2004 Oct 19;44(8):1690-9 12767654 - J Am Coll Cardiol. 2003 May 21;41(10):1721-4 15860518 - Eur Heart J. 2005 Sep;26(18):1838-45 20956984 - Nat Rev Cardiol. 2010 Dec;7(12):700-10 12676819 - Circ Res. 2003 May 16;92(9):1049-55 20051633 - J Clin Invest. 2010 Jan;120(1):20-8 20458006 - Hypertension. 2010 Jun;55(6):1389-97 19349335 - Circulation. 2009 Apr 7;119(13):1824-31 8958214 - J Clin Invest. 1996 Dec 1;98(11):2512-23 20309960 - Stem Cells. 2010 May;28(5):903-4 |
| References_xml | – reference: 16698918 - Proc Natl Acad Sci U S A. 2006 May 23;103(21):8155-60 – reference: 9462531 - Circulation. 1998 Jan 27;97(3):282-9 – reference: 10791985 - J Cell Biol. 2000 May 1;149(3):731-40 – reference: 15883216 - Circulation. 2005 May 17;111(19):2486-93 – reference: 19738142 - Circulation. 2009 Sep 22;120(12):1075-83, 7 p following 1083 – reference: 19208649 - Eur Heart J. 2009 Jun;30(11):1313-21 – reference: 9701245 - Nat Med. 1998 Aug;4(8):929-33 – reference: 17592079 - Circulation. 2007 Jul 10;116(2):163-73 – reference: 18794392 - Circulation. 2008 Sep 30;118(14):1425-32 – reference: 11413075 - Circulation. 2001 Jun 19;103(24):2885-90 – reference: 18288183 - Nature. 2008 Feb 21;451(7181):937-42 – reference: 16476845 - Circulation. 2006 Feb 21;113(7):1005-14 – reference: 17964040 - J Am Coll Cardiol. 2007 Oct 30;50(18):1761-7 – reference: 15767470 - Hypertension. 2005 Apr;45(4):526-9 – reference: 12679204 - J Am Coll Cardiol. 2003 Apr 2;41(7):1078-83 – reference: 16159869 - Circulation. 2005 Aug 30;112(9 Suppl):I73-80 – reference: 19436808 - Tex Heart Inst J. 2009;36(2):140-4 – reference: 18566313 - Circ Res. 2008 Jun 20;102(12):1471-82 – reference: 20211295 - Am Heart J. 2010 Mar;159(3):354-60 – reference: 15219514 - Am J Cardiol. 2004 Jul 1;94(1):92-5 – reference: 16904174 - Cell. 2006 Aug 25;126(4):663-76 – reference: 15389244 - Am Heart J. 2004 Sep;148(3):531-7 – reference: 16990383 - N Engl J Med. 2006 Sep 21;355(12):1199-209 – reference: 14505575 - Cell. 2003 Sep 19;114(6):763-76 – reference: 9616709 - Ann N Y Acad Sci. 1997 Dec 31;831:145-67 – reference: 17709737 - Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14068-73 – reference: 17691968 - Curr Neurovasc Res. 2007 Aug;4(3):153-60 – reference: 18556575 - Circ Res. 2008 Jul 18;103(2):194-202 – reference: 19429633 - Eur Heart J. 2009 Jun;30(11):1310-2 – reference: 18728188 - Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12991-6 – reference: 12370212 - Circulation. 2002 Oct 8;106(15):1913-8 – reference: 11489932 - J Clin Invest. 2001 Aug;108(3):391-7 – reference: 19833262 - J Am Coll Cardiol. 2009 Oct 20;54(17):1619-26 – reference: 20956984 - Nat Rev Cardiol. 2010 Dec;7(12):700-10 – reference: 15016484 - Lancet. 2004 Mar 6;363(9411):751-6 – reference: 15489105 - J Am Coll Cardiol. 2004 Oct 19;44(8):1690-9 – reference: 11744011 - Cardiovasc Res. 2002 Jan;53(1):31-47 – reference: 17098754 - Eur Heart J. 2006 Dec;27(23):2775-83 – reference: 16678200 - J Mol Cell Cardiol. 2006 Jun;40(6):799-809 – reference: 18467662 - Stem Cells. 2008 Jul;26(7):1749-57 – reference: 15364865 - Circulation. 2004 Sep 14;110(11 Suppl 1):II213-8 – reference: 19773226 - Eur Heart J. 2009 Dec;30(24):2978-84 – reference: 17283259 - Circulation. 2007 Feb 20;115(7):896-908 – reference: 17562958 - Circulation. 2007 Jun 26;115(25):3165-72 – reference: 19996415 - Circ Heart Fail. 2010 Jan;3(1):89-96 – reference: 12695305 - Circulation. 2003 Apr 29;107(16):2134-9 – reference: 11548889 - Jpn Circ J. 2001 Sep;65(9):845-7 – reference: 17283208 - J Exp Med. 2007 Feb 19;204(2):405-20 – reference: 9020076 - Science. 1997 Feb 14;275(5302):964-7 – reference: 19342590 - Science. 2009 Apr 3;324(5923):98-102 – reference: 19520249 - J Am Coll Cardiol. 2009 Jun 16;53(24):2262-9 – reference: 17875967 - Circulation. 2007 Oct 9;116(15):1683-92 – reference: 16256862 - J Am Coll Cardiol. 2005 Nov 1;46(9):1643-8 – reference: 16990384 - N Engl J Med. 2006 Sep 21;355(12):1210-21 – reference: 17414713 - Transplantation. 2007 Mar 27;83(6):783-90 – reference: 15860518 - Eur Heart J. 2005 Sep;26(18):1838-45 – reference: 20660394 - N Engl J Med. 2010 Oct 7;363(15):1397-409 – reference: 18285565 - Circulation. 2008 Mar 4;117(9):1189-200 – reference: 19213953 - Circ Res. 2009 Feb 27;104(4):e30-41 – reference: 16990385 - N Engl J Med. 2006 Sep 21;355(12):1222-32 – reference: 16159812 - Circulation. 2005 Aug 30;112(9 Suppl):I178-83 – reference: 12707230 - Circulation. 2003 May 13;107(18):2294-302 – reference: 15001531 - Circ Res. 2004 Apr 2;94(6):e56-60 – reference: 18523058 - Eur Heart J. 2008 Aug;29(15):1807-18 – reference: 20083719 - Circulation. 2010 Jan 19;121(2):325-35 – reference: 15321944 - Circ Res. 2004 Aug 20;95(4):343-53 – reference: 14613737 - Eur Heart J. 2003 Nov;24(22):2012-20 – reference: 15655116 - Hypertension. 2005 Mar;45(3):321-5 – reference: 17823373 - Circ Res. 2007 Oct 26;101(9):910-8 – reference: 19789401 - Eur J Heart Fail. 2009 Oct;11(10):973-9 – reference: 16002755 - Circ Res. 2005 Jul 8;97(1):8-15 – reference: 20458006 - Hypertension. 2010 Jun;55(6):1389-97 – reference: 20576835 - Eur J Heart Fail. 2010 Jul;12(7):721-9 – reference: 12517467 - Lancet. 2003 Jan 4;361(9351):45-6 – reference: 17090821 - J Invasive Cardiol. 2006 Nov;18(11):552-6 – reference: 19095934 - Science. 2008 Dec 19;322(5909):1811-5 – reference: 19620500 - Circulation. 2009 Aug 4;120(5):408-16 – reference: 20309960 - Stem Cells. 2010 May;28(5):903-4 – reference: 16510465 - Eur Heart J. 2006 Apr;27(8):929-35 – reference: 19454638 - JAMA. 2009 May 20;301(19):1997-2004 – reference: 19099374 - Stem Cells Dev. 2009 Jun;18(5):683-92 – reference: 17075009 - Circulation. 2006 Nov 14;114(20):2163-9 – reference: 18402895 - J Am Coll Cardiol. 2008 Apr 15;51(15):1429-37 – reference: 20051633 - J Clin Invest. 2010 Jan;120(1):20-8 – reference: 12714439 - Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 – reference: 16543252 - Eur Heart J. 2006 Jun;27(11):1338-40 – reference: 19958962 - J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86 – reference: 17056665 - Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1095-104 – reference: 15764613 - Eur Heart J. 2005 Jun;26(12):1188-95 – reference: 12628955 - Circulation. 2003 Mar 11;107(9):1322-8 – reference: 12196341 - Circulation. 2002 Aug 27;106(9):1133-9 – reference: 15851598 - Circulation. 2005 May 3;111(17):2198-202 – reference: 15192775 - Thorac Cardiovasc Surg. 2004 Jun;52(3):152-8 – reference: 18371446 - Cell Stem Cell. 2008 Mar 6;2(3):205-13 – reference: 15246726 - Lancet. 2004 Jul 10-16;364(9429):141-8 – reference: 19704095 - Circulation. 2009 Sep 8;120(10):876-87 – reference: 18293890 - Cell Transplant. 2007;16(9):919-25 – reference: 17145991 - Circulation. 2006 Dec 19;114(25):2823-30 – reference: 12767654 - J Am Coll Cardiol. 2003 May 21;41(10):1721-4 – reference: 20925550 - N Engl J Med. 2010 Oct 7;363(15):1471-2 – reference: 16003373 - Nat Biotechnol. 2005 Jul;23(7):845-56 – reference: 18669889 - Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1584-95 – reference: 15687132 - Circulation. 2005 Feb 1;111(4):442-50 – reference: 19341621 - Cell Stem Cell. 2009 Apr 3;4(4):313-23 – reference: 12676819 - Circ Res. 2003 May 16;92(9):1049-55 – reference: 11851363 - J Mol Cell Cardiol. 2002 Feb;34(2):241-9 – reference: 20534467 - Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11008-13 – reference: 18793110 - Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1071-82 – reference: 12517468 - Lancet. 2003 Jan 4;361(9351):47-9 – reference: 12900340 - Circulation. 2003 Aug 19;108(7):863-8 – reference: 12473544 - Circulation. 2002 Dec 10;106(24):3009-17 – reference: 14680727 - J Am Coll Cardiol. 2003 Dec 17;42(12):2063-9 – reference: 15242981 - Circ Res. 2004 Jul 9;95(1):9-20 – reference: 19544463 - Stem Cells. 2009 Jul;27(7):1571-81 – reference: 16172284 - Circulation. 2005 Sep 20;112(12):1748-55 – reference: 19349334 - Circulation. 2009 Apr 7;119(13):1814-23 – reference: 8958214 - J Clin Invest. 1996 Dec 1;98(11):2512-23 – reference: 18625890 - Circulation. 2008 Jul 29;118(5):507-17 – reference: 16256864 - J Am Coll Cardiol. 2005 Nov 1;46(9):1651-8 – reference: 18308163 - J Am Coll Cardiol. 2008 Mar 4;51(9):933-43 – reference: 19349335 - Circulation. 2009 Apr 7;119(13):1824-31 – reference: 15336842 - Int J Cardiol. 2004 Jun;95 Suppl 1:S29-33 – reference: 19540842 - J Mol Cell Cardiol. 2009 Sep;47(3):411-8 – reference: 16413875 - Lancet. 2006 Jan 14;367(9505):113-21 – reference: 16520413 - Circulation. 2006 Mar 14;113(10):1287-94 – reference: 18672162 - J Am Coll Cardiol. 2008 Aug 5;52(6):428-34 – reference: 20453167 - Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1088-93 – reference: 17984132 - Eur Heart J. 2007 Dec;28(24):2998-3005 – reference: 20861135 - Eur J Heart Fail. 2010 Oct;12(10):1111-21 – reference: 17533201 - Arch Intern Med. 2007 May 28;167(10):989-97 – reference: 15358665 - Circ Res. 2004 Oct 1;95(7):742-8 – reference: 19508995 - Eur Heart J. 2009 Aug;30(16):1986-94 – reference: 19226183 - PLoS Med. 2009 Feb 17;6(2):e1000029 – reference: 20421520 - Circulation. 2010 May 11;121(18):1992-2000 – reference: 16582915 - Nat Med. 2006 Apr;12(4):452-8 – reference: 16061805 - Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11474-9 |
| SSID | ssj0008616 |
| Score | 2.4782069 |
| SecondaryResourceType | review_article |
| Snippet | In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel therapeutic... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1197 |
| SubjectTerms | AC133 Antigen Acute Disease Antigens, CD - physiology Antigens, CD34 - physiology Chronic Disease Embryonic Stem Cells - transplantation Forecasting Glycoproteins - physiology Hematopoietic Stem Cell Mobilization - methods Humans Mesenchymal Stem Cell Transplantation - methods Myoblasts, Skeletal - transplantation Myocardial Infarction - therapy Myocardial Ischemia - therapy Peptides - physiology Pluripotent Stem Cells - transplantation Stem Cell Transplantation - methods |
| Title | Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21362705 https://www.proquest.com/docview/867322155 |
| Volume | 32 |
| WOSCitedRecordID | wos000290812000010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w9y8GjYJptNEy8ionhxEVTY29JMplhhu7pdBf-9k7arJ_HgpbeUZDKTb5L5ko-x0wQ0oJNd4fKeEZRSg7DGowhWSpNAlisXarGJtN-3g4G7b7k5VUurnK2J9UIdxhDPyDvWpOR7hH4Xr28iikbF4mqroDHPFruUyURGVzr4eSzcmlr5lBBKCWd0r61S0h6-g--TKBg9feng8ySR9vf8ssaZm7V_9nCdrbYJJr9sPGKDzWG5yZbv2hL6FisepjjiWRl4pGZhjOgJj8f3IgJa4M2FrE9elLyoIqV-VACvR8HbYs55bEnugWecQLGhFMRnWc_qv8JMnaXaZk83149Xt6LVWxCgnZwKrdGBBZojlKkHF2uoFLGgYxqZdLM8GOt7MncWk1x5FTLa7hgDhG_BGK_VDlsoxyXuMQ4-qJCgyzCz2nqZOeWDVoCabOQ17DM-s-GQOhxHmZU4fq-G31bcZ7vNPAxfm3c3hkoS2qZJ7-DvxodspTn8jczEI7aYUyzjMVuCj2lRTU5qP6Fv__7uCzjFynQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stem+and+progenitor+cell-based+therapy+in+ischaemic+heart+disease%3A+promise%2C+uncertainties%2C+and+challenges&rft.jtitle=European+heart+journal&rft.au=Tongers%2C+J%C3%B6rn&rft.au=Losordo%2C+Douglas+W&rft.au=Landmesser%2C+Ulf&rft.date=2011-05-01&rft.issn=1522-9645&rft.eissn=1522-9645&rft.volume=32&rft.issue=10&rft.spage=1197&rft_id=info:doi/10.1093%2Feurheartj%2Fehr018&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-9645&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-9645&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-9645&client=summon |